Core Viewpoint - Xinhua Pharmaceutical's stock has shown a modest increase in recent trading sessions, with a year-to-date rise of 5.05%, despite a decline over the past 60 days [1][2]. Group 1: Stock Performance - On November 7, Xinhua Pharmaceutical's stock rose by 2.33%, reaching 16.24 CNY per share, with a trading volume of 1.20 billion CNY and a turnover rate of 1.52% [1]. - The stock has experienced a net inflow of 620.05 thousand CNY from major funds, with significant buying activity from large orders [1]. - Year-to-date, the stock has appeared on the "Dragon and Tiger List" once, with a net purchase of 15.67 million CNY on January 6 [1]. Group 2: Financial Performance - For the period from January to September 2025, Xinhua Pharmaceutical reported a revenue of 6.763 billion CNY, reflecting a year-on-year growth of 0.42%, while the net profit attributable to shareholders decreased by 25.53% to 256 million CNY [2]. - Cumulative cash dividends since the A-share listing amount to 1.17 billion CNY, with 495 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 7.60% to 70,700, with an average of 0 circulating shares per person [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several ETFs, all of which have seen a reduction in their holdings compared to the previous period [3].

Group 1 - The stock price of Xinhua Pharmaceutical (000756) closed at 15.91 yuan on November 4, 2025, down 0.25% with a turnover rate of 1.96% and a trading volume of 96,400 shares, amounting to a total transaction value of 153 million yuan [1] - The company has a diverse product range including raw materials, formulations, and pharmaceutical intermediates, with the sales volume of the winning products from the national medical procurement policy being relatively small [2] - After winning bids under the national medical procurement policy, the gross margin of the winning products has decreased, but the company can mitigate this impact through economies of scale, refined management, and expanding market share [2] Group 2 - On November 4, the net inflow of main funds was 23.77 million yuan, accounting for 15.57% of the total transaction value, while retail investors experienced a net outflow of 14.34 million yuan, representing 9.39% of the total transaction value [3] - The implementation of the procurement policy has led to an improvement in the payment settlement cycle for the company as the National Healthcare Security Administration gradually expands the direct settlement range of medical insurance funds with pharmaceutical companies [2]

Core Viewpoint - The company, XinHua Pharmaceutical, has indicated that it operates with a diverse range of products including raw materials, formulations, and pharmaceutical intermediates, with a relatively small proportion of sales coming from awarded products [1] Group 1: Impact of National Drug Procurement Policy - The gross margin of awarded products has decreased following the implementation of the national drug procurement policy [1] - The company aims to mitigate the impact of this margin decline through scale effects, refined management, and expanding market share [1] Group 2: Improvement in Payment Settlement - The implementation of the national procurement policy has led to an improvement in the payment settlement cycle for the company, as the National Healthcare Security Administration gradually expands the direct settlement range of medical insurance funds with pharmaceutical companies [1]

Group 1 - Tianhua New Energy announced that CATL plans to acquire 12.95% of the company's shares, totaling 1.08 billion shares at a price of 24.49 yuan per share, amounting to 2.635 billion yuan [2] - Zhenyu Technology plans to invest 2.11 billion yuan in the production of humanoid robot precision modules and components, in collaboration with Ninghai County [2] - Tianqi Co., Ltd. signed a strategic cooperation framework agreement with Foxconn to deploy at least 2,000 embodied intelligent robots in the next five years [2] Group 2 - Qingyue Technology is under investigation by the China Securities Regulatory Commission for suspected false financial reporting [3] - Bestme's actual controller is being investigated for failing to fulfill mandatory tender offer obligations and information disclosure violations [4] Group 3 - Inno Group announced the termination of a major asset restructuring plan to acquire 80% of Zhizhe Tongxing Brand Management Consulting [6] - Weigao Blood Purification plans to acquire 100% of Weigao Purui Pharmaceutical Packaging, with stock resuming trading on November 3 [7] - Zhongyuan Co., Ltd. is undergoing a change in actual control, with stock resuming trading on November 3 [8] Group 4 - China General Nuclear Power has completed the payment for the acquisition of shares in Huizhou Nuclear Power and three other companies [9] - Baichuan Energy plans to acquire 22.86% of Xi'an Zhongke Optoelectronics for 215 million yuan [9] - Lan科高新 has changed its major asset restructuring plan to acquire 51% of China Air Separation [9]

新华制药公告，近日收到国家药品监督管理局核准签发的阿仑膦酸钠口服溶液《药品注册证书》。该药 品适用于治疗绝经后妇女的骨质疏松症，以预防髋部和脊柱骨折（椎骨压缩性骨折）和男性骨质疏松以 增加骨量。2024年阿仑膦酸钠在包括中国公立医院、公立基层医疗机构、零售药店在内的三大终端销售 额达人民币7.2亿元。 ...

人民财讯10月31日电，新华制药（000756）10月31日公告，近日，公司收到国家药品监督管理局核准签 发的阿仑膦酸钠口服溶液《药品注册证书》。阿仑膦酸钠口服溶液适用于治疗绝经后妇女的骨质疏松 症，以预防髋部和脊柱骨折(椎骨压缩性骨折)和男性骨质疏松以增加骨量。根据有关统计数据，2024年 阿仑膦酸钠在包括中国公立医院、公立基层医疗机构、零售药店在内的三大终端销售额达7.2亿元。 ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received the drug registration certificate for Alendronate Sodium Oral Solution from the National Medical Products Administration, indicating a significant advancement in its product offerings for osteoporosis treatment [1] Company Summary - The approval of Alendronate Sodium Oral Solution is aimed at treating osteoporosis in postmenopausal women and preventing hip and spinal fractures, as well as increasing bone mass in men with osteoporosis [1]

证券代码：000756 证券简称：新华制药 公告编号：2025-65 山东新华制药股份有限公司 关于获得《药品注册证书》等相关情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药 品监督管理局核准签发的阿仑膦酸钠口服溶液（以下简称"本品"）《药品注册证书》。现将 相关情况公告如下： 一、基本情况 药品名称：阿仑膦酸钠口服溶液 剂型：口服溶液剂 规格：75ml:70mg（按C4H13NO7P2计） 药品分类：处方药 受理号：CYHS2401018、CYHB2402066 药品批准文号：国药准字 H20255791 证书编号：2025S03243 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附 执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 二、其他相关信息 2024年4月，山东朗诺制药有限公司（以下简称"山东朗诺"）向国家药品监督管理局药 品审评中心（ ...

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Alendronate Sodium Oral Solution, which is indicated for the treatment of osteoporosis in postmenopausal women and men, aimed at preventing hip and vertebral fractures [1] Company Summary - The newly approved Alendronate Sodium Oral Solution is designed to increase bone mass and prevent fractures in specific patient populations [1] - The projected sales revenue for Alendronate Sodium in 2024 across major distribution channels, including public hospitals, grassroots medical institutions, and retail pharmacies, is estimated to reach RMB 720 million [1]

据悉，阿仑膦酸钠口服溶液适用于治疗绝经后妇女的骨质疏松症，以预防髋部和嵴柱骨折(椎骨压缩性 骨折)和男性骨质疏松以增加骨量。根据有关统计数据，2024年阿仑膦酸钠在包括中国公立医院、公立 基层医疗机构、零售药店在内的叁大终端销售额达人民币7.2亿元。 智通财经APP讯，山东新华制药股份(00719)发布公告，近日，山东新华制药股份有限公司收到国家药品 监督管理局核准签发的阿仑膦酸钠口服溶液《药品注册证书》。 ...